A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
← catalyst calendarNCT06079398 · readout ≤ 499 d
Sponsored by Ascendis Pharma A/S (industry) · ASND — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
72estimated
Sites
18
Countries
Australia, Austria, Canada +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-23 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Achondroplasia
Interventions
- Drug: Navepegritide
- Drug: Placebo for Navepegritide
Primary outcomes
what the primary-completion date above is the date OFTo evaluate the safety and tolerability of Navepegritide
measured 52 weeks
To evaluate the effect of Navepegritide on growth
measured 52 weeks
Permalink · ASND's whole pipeline · Catalyst calendar · Every registered study · What changed